


**WHAT IS CLAIMED:**

1. A compound of formula I:



5

(I)

wherein:

R<sub>1</sub> is C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -CH<sub>2</sub>-C<sub>3</sub>-C<sub>6</sub> cycloalkyl, pyridinyl, -CH<sub>2</sub>-pyridinyl, phenyl or benzyl, the rings of the cycloalkyl, pyridinyl, phenyl and benzyl groups may be optionally substituted by from 1 to 3 groups selected from the group  
10 chemistry of halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl, -O-C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, -OH, -NH<sub>2</sub>, and -NO<sub>2</sub>;

R<sub>2</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -CH<sub>2</sub>-C<sub>3</sub>-C<sub>6</sub> cycloalkyl, or C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl;

15

R<sub>3</sub> is hydrogen, halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -CH<sub>2</sub>-C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -NH<sub>2</sub>, or -NO<sub>2</sub>;

R<sub>4</sub> is phenyl, benzyl, benzyloxy, pyridinyl, or -CH<sub>2</sub>-pyridinyl, wherein the rings  
20 of these groups may be optionally substituted by 1 to 3 groups selected from the group chemistry of halogen, C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl, -O-C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, -OH, -NH<sub>2</sub>, and -NO<sub>2</sub>;


R<sub>8</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -CH<sub>2</sub>-C<sub>3</sub>-C<sub>6</sub> cycloalkyl, or C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl, aryl, substituted aryl, alkyl-aryl, or substituted alkyl-aryl; and

R<sub>9</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> branched alkyl, C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl, 4-

hydroxybenzyl, 3-indolymethylene, 4-imidazolylmethylene,  $\text{HSCH}_2^-$ ,  $\text{CH}_3\text{SCH}_2\text{CH}_2^-$ ,  $\text{H}_2\text{NC}(=\text{O})\text{CH}_2^-$ ,  $\text{H}_2\text{NC}(=\text{O})\text{CH}_2\text{CH}_2^-$ ,  $\text{HO}_2\text{CCH}_2^-$ ,  $\text{HO}_2\text{CCH}_2\text{CH}_2^-$ ,  $\text{H}_2\text{NCH}_2\text{CH}_2\text{CH}_2\text{CH}_2^-$ ,  $\text{H}_2\text{NC}(=\text{NH})\text{NHCH}_2\text{CH}_2\text{CH}_2^-$ , or taken together with  $\text{R}_8$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2^-$ ;


5 or a pharmaceutically acceptable salt or ester form thereof.

2. A compound of Claim 1 having the formulas:



10 wherein  $\text{R}_1$ ,  $\text{R}_2$ ,  $\text{R}_3$ ,  $\text{R}_4$ ,  $\text{R}_8$  and  $\text{R}_9$  are as defined in Claim 1, or a pharmaceutically acceptable salt or ester form thereof.

3. A compound of Claim 1 having the formulas:



15

(IV)

(V)

wherein:

$\text{R}_1$  is  $\text{C}_1\text{-C}_8$  alkyl,  $\text{C}_3\text{-C}_6$  cycloalkyl,  $-\text{CH}_2\text{-C}_3\text{-C}_6$  cycloalkyl, or benzyl, wherein the rings of the cycloalkyl and benzyl groups may be optionally substituted by from 1

20 to 3 groups selected from halogen,  $\text{C}_1\text{-C}_3$  alkyl,  $\text{C}_1\text{-C}_3$  perfluoroalkyl,  $-\text{O-C}_1\text{-C}_3$  perfluoroalkyl, preferably  $-\text{O-CF}_3$ ,  $\text{C}_1\text{-C}_3$  alkoxy,  $-\text{OH}$ ,  $-\text{NH}_2$ , or  $-\text{NO}_2$ ;

$R_2$  is hydrogen,  $C_1\text{-}C_6$  alkyl,  $C_3\text{-}C_6$  cycloalkyl,  $-\text{CH}_2\text{-}C_3\text{-}C_6$  cycloalkyl, or  $C_1\text{-}C_3$  perfluoroalkyl;

5        $R_3$  is hydrogen, halogen,  $C_1\text{-}C_6$  alkyl,  $C_1\text{-}C_3$  perfluoroalkyl,  $C_1\text{-}C_6$  alkoxy,  $C_3\text{-}C_6$  cycloalkyl,  $-\text{CH}_2\text{-}C_3\text{-}C_6$  cycloalkyl,  $-\text{NH}_2$ , or  $-\text{NO}_2$ ;

10       $R_5$ ,  $R_6$  and  $R_7$  are each independently hydrogen, halogen,  $C_1\text{-}C_3$  alkyl,  $C_1\text{-}C_3$  perfluoroalkyl,  $-\text{O}\text{-}C_1\text{-}C_3$  perfluoroalkyl,  $C_1\text{-}C_3$  alkoxy,  $-\text{OH}$ ,  $-\text{NH}_2$ , or  $-\text{NO}_2$ ;

10

$R_8$  is hydrogen,  $C_1\text{-}C_6$  alkyl,  $C_3\text{-}C_6$  cycloalkyl,  $-\text{CH}_2\text{-}C_3\text{-}C_6$  cycloalkyl, or  $C_1\text{-}C_3$  perfluoroalkyl, aryl, substituted aryl, alkyl-aryl, or substituted alkyl-aryl;

15

$R_9$  is hydrogen,  $C_1\text{-}C_6$  alkyl,  $C_3\text{-}C_6$  branched alkyl,  $C_1\text{-}C_6$  hydroxyalkyl, 4-hydroxybenzyl, 3-indolylmethylen, 4-imidazolylmethylene,  $\text{HSCH}_2$ -,  $\text{CH}_3\text{SCH}_2\text{CH}_2$ -,  $\text{H}_2\text{NC}(=\text{O})\text{CH}_2$ -,  $\text{H}_2\text{NC}(=\text{O})\text{CH}_2\text{CH}_2$ -,  $\text{HO}_2\text{CCH}_2$ -,  $\text{HO}_2\text{CCH}_2\text{CH}_2$ -,  $\text{H}_2\text{NCH}_2\text{CH}_2\text{CH}_2\text{CH}_2$ -,  $\text{H}_2\text{NC}(=\text{NH})\text{NHCH}_2\text{CH}_2\text{CH}_2$ -, or taken together with  $R_8$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2$ ;

20

      or a pharmaceutically acceptable salt or ester form thereof.

4.       The compound of Claim 1 which is {[[(1-(4-*tert*-butylbenzyl)-5-(3-methylphenyl)-1*H*-indol-3-yl](oxo)acetyl]amino}acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

25


5.       The compound of Claim 1 which is 2-[(2-{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1*H*-indol-3-yl}-2-oxoacetyl)amino]acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

30

6.       The compound of Claim 1 which is 2-[(2-{1-Benzyl-5-[3-(trifluoromethoxy)phenyl]-1*H*-indol-3-yl}-2-oxoacetyl)(methyl)amino]acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

7. A method of inhibiting plasminogen activator inhibitor-1 in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of compound of formula:

5



(I)

wherein:

10       $R_1$  is  $C_1-C_8$  alkyl,  $C_3-C_6$  cycloalkyl,  $-CH_2-C_3-C_6$  cycloalkyl, pyridinyl,  $-CH_2-$  pyridinyl, phenyl or benzyl, the rings of the cycloalkyl, pyridinyl, phenyl and benzyl groups may be optionally substituted by from 1 to 3 groups selected from the group chemistry of halogen,  $C_1-C_6$  alkyl,  $C_1-C_3$  perfluoroalkyl,  $-O-C_1-C_3$  perfluoroalkyl,  $C_1-C_3$  alkoxy,  $-OH$ ,  $-NH_2$ , and  $-NO_2$ ;

15       $R_2$  is hydrogen,  $C_1-C_6$  alkyl,  $C_3-C_6$  cycloalkyl,  $-CH_2-C_3-C_6$  cycloalkyl, or  $C_1-C_3$  perfluoroalkyl;

20       $R_3$  is hydrogen, halogen,  $C_1-C_6$  alkyl,  $C_1-C_3$  perfluoroalkyl,  $C_1-C_6$  alkoxy,  $C_3-C_6$  cycloalkyl,  $-CH_2-C_3-C_6$  cycloalkyl,  $-NH_2$ , or  $-NO_2$ ;

25       $R_4$  is phenyl, benzyl, benzyloxy, pyridinyl, or  $-CH_2$ -pyridinyl, wherein the rings of these groups may be optionally substituted by 1 to 3 groups selected from the group chemistry of halogen,  $C_1-C_3$  alkyl,  $C_1-C_3$  perfluoroalkyl,  $-O-C_1-C_3$  perfluoroalkyl,  $C_1-C_3$  alkoxy,  $-OH$ ,  $-NH_2$ , and  $-NO_2$ ;

25       $R_8$  is hydrogen,  $C_1-C_6$  alkyl,  $C_3-C_6$  cycloalkyl,  $-CH_2-C_3-C_6$  cycloalkyl, or  $C_1-C_3$  perfluoroalkyl, aryl, substituted aryl, alkyl-aryl, or substituted alkyl-aryl; and

$R_9$  is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> branched alkyl, C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl, 4-hydroxybenzyl, 3-indolylmethylene, 4-imidazolylmethylene, HSCH<sub>2</sub>-, CH<sub>3</sub>SCH<sub>2</sub>CH<sub>2</sub>-, H<sub>2</sub>NC(=O)CH<sub>2</sub>-, H<sub>2</sub>NC(=O)CH<sub>2</sub>CH<sub>2</sub>-, HO<sub>2</sub>CCH<sub>2</sub>-, HO<sub>2</sub>CCH<sub>2</sub>CH<sub>2</sub>-,  
5 H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, H<sub>2</sub>NC(=NH)NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, or taken together with R<sub>8</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>;

or a pharmaceutically acceptable salt or ester form thereof.

10 8. A pharmaceutical composition comprising pharmaceutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt or ester form thereof, and a pharmaceutically acceptable excipient or carrier.

15 9. A method for treatment of thrombosis or fibrinolytic impairment in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

20 10. A method of Claim 9 wherein the thrombosis or fibrinolytic impairment is associated with formation of atherosclerotic plaques, venous and arterial thrombosis, myocardial ischemia, atrial fibrillation, deep vein thrombosis, coagulation syndromes, pulmonary fibrosis, cerebral thrombosis, thromboembolic complications of surgery or peripheral arterial occlusion.

25 11. A method for the treatment of peripheral arterial disease in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

30 12. A method for the treatment of stroke associated with or resulting from atrial fibrillation in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

13. A method for the treatment of deep vein thrombosis in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective

amount of a compound of Claim 1.

14. A method for the treatment of myocardial ischemia in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

15. A method for treatment of cardiovascular disease caused by noninsulin dependent diabetes mellitus in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

16. A method for the treatment of the formation of atherosclerotic plaques in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

15 17. A method for the treatment of chronic obstructive pulmonary disease in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

20 18. A method for the treatment of renal fibrosis in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

25 19. A method for the treatment of polycystic ovary syndrome in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

20. A method for the treatment of Alzheimer's disease in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

21. A method for the treatment of cancer in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a

compound of Claim 1.